Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida. Show more

Location: 601 Brickell Key Drive, Miami, FL, 33131, United States | Website: https://www.smmttx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

13.44B

52 Wk Range

$15.55 - $36.91

Previous Close

$18.12

Open

$17.76

Volume

5,527,902

Day Range

$17.76 - $18.54

Enterprise Value

13.15B

Cash

297.9M

Avg Qtr Burn

-51.72M

Insider Ownership

84.35%

Institutional Own.

13.55%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ivonescimab + chemotherapy Details
EGFR-mutated, advanced non-squamous NSCLC (2L+ EGFRm NSCLC)

BLA

Submission

Ivonescimab + chemotherapy Details
EGFR-mutated, advanced non-squamous NSCLC

BLA

Submission

Ivonescimab (SMT112) Details
1L Non-small cell lung carcinoma

BLA

Submission

Ivonescimab Details
1L PD-L1 positive Non-small cell lung carcinoma

Phase 3

Data readout

Ivonescimab Details
PD-L1 positive NSCLC

Phase 3

Update

Phase 2

Update

Ridinilazole Details
Intestinal infection, Bacterial infection

Failed

Discontinued